

Special Issue

Parasite-Mediated Immune Responses

Message from the Guest Editor

Malaria infection induces complex and diverse immune responses. The emergence of multi-drug resistance highlights the importance of discovering novel targets/drugs to combat malaria. One target drug which is currently most explored is the “host and parasite’s ubiquitin system”. Ubiquitination is associated with various diseases. E3 ubiquitin ligase regulates parasite growth and host virulence by generating different immune responses. E3 ubiquitin ligase (March1), clustered with interferon-stimulated genes alters immune cell populations in malaria-infected hosts in March1 deficiency. Its deficiency increases CD86+ DC populations and levels of IFN- γ and interleukin 10 post-infection, leading to improved host survival. Another ubiquitin ligase (March8) suppressed the binding of cGAS to DNA, resulting in the inhibition of the production of cGAMP and type I IFN and enhancing the interaction of March8 with cGAS which may be a strategy to treat some autoimmune diseases. Thus, E3 ligase functions in innate immune responses and provides potential avenues for activating antiparasitic immunity and enhancing vaccine efficacy.

Guest Editor

Dr. Brajesh Kumar Singh

Department of Pathology and Laboratory Medicine, Brown University,
Center for International Health Research, 55 Claverick Street, Suite 101,
Providence, RI 02903-4923, USA

Deadline for manuscript submissions

closed (30 September 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/136552

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).